Fig. 1

ADAM12 is upregulated in CRC and is expressed in the CRC stroma. Expression levels of ADAM12 are shown in tumor versus normal tissue. All datasets used are indicated in Supplementary Table S1 (A). In left panel, expression of ADAM12 in cell lines is compared to pooled Affymetrix data from bulk tumor (GSE44861 and GSE68468). In right panel, showing expression in sorted cell populations from dissociated tumors. CD31, endothelial cells; CD45, immune cells; EpCAM; epithelial (tumor) cells; FAP, (myo) fibroblast marker (B). Expression levels of ADAM12 in tumor tissue compared to stromal tissue in microdissected CRC and non-cancerous tissue (C). Expression of ADAM12 was correlated to stromal activation markers in the AMC-AJCCII-90 dataset. Collagen type 1 alpha 1 (COL1A1) R2 = 0.6371, p < 2.2 × 10–16; α-smooth muscle actin (ACTA2) R2 = 0.4736, p = 4.0 × 10–14; Fibroblast Activation Protein (FAP) R2 = 0.7450, p < 2.2 × 10–16. Epithelial markers: cytokeratin 19 (KRT19) R2 = -0.0082, p = 0.6014; Epithelial Cell Adhesion Molecule (EPCAM) R2 = 0.1106, P = 0.0007; E-cadherin (CDH1) R2 = 0.2123, p = 2.9 × 10–6 (D). Species specific transcript analysis of ADAM paralogs in patient-derived xenografts was performed. First panel shows mouse reads (Adam), second panel shows human reads (ADAM) (E). P-value indicated underneath panels is by ANOVA test, comparing conditions within panel. Asterisks indicate significance level tested by T-test between mAdam12 and hADAM12 per dataset